DRW Securities’s Travere Therapeutics TVTX Stock Holding History

DRW Securities’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,518	Closed	-$312K	–	1489
2026 Q1	$312K	Buy	+10,518	New	+$314K	﹤0.01%	868
2024 Q3	–	Sell	-11,598	Closed	-$95.3K	–	746
2024 Q2	$95.3K	Buy	+11,598	New	+$78.1K	﹤0.01%	495
2021 Q1	–	Sell	-100,000	Closed	-$2.73M	–	221
2020 Q4	$2.73M	Sell	100,000 -20,000	-17%	-$467K	0.1%	47
2020 Q3	$2.21M	Hold	120,000	–	–	0.12%	49
2020 Q2	$2.45M	Sell	120,000 -82	-0.1%	-$1.31K	0.11%	56
2020 Q1	$1.75M	Sell	120,082 -60,000	-33%	-$903K	0.06%	63
2019 Q4	$2.56M	Hold	180,082	–	–	0.1%	63
2019 Q3	$2.09M	Buy	+180,082	New	+$2.98M	0.14%	50
2016 Q1	–	Sell	-17,500	Closed	-$338K	–	91
2015 Q4	$338K	Buy	+17,500	New	+$350K	0.03%	60

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DRW Securities's TVTX Position: Q2 2026 in Review

DRW Securities sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 10,518 shares — an estimated $312K sold.

DRW Securities first reported a position in TVTX in Q4 2015 and held it in 9 quarters. The position peaked at $2.73M in Q4 2020. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

DRW Securities reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
DRW Securities sold 10,518 Travere Therapeutics shares in Q2 2026, an estimated $312K.
DRW Securities first reported a position in Travere Therapeutics in Q4 2015 and held it in 9 quarters.
DRW Securities's Travere Therapeutics position peaked at $2.73M in Q4 2020.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.